Q-omics provides the consensus-scored AMOTL2 profile across patient tissues and cancer cell-line models. AMOTL2 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, AMOTL2 is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, AMOTL2 protein abundance shows 23,920 significant protein co-abundance associations, with the highest sampling consensus in UCEC. Together, these results highlight UVM, COAD, and UCEC as cancer lineages where AMOTL2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for AMOTL2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes AMOTL2 survival associations across molecular data types. AMOTL2 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (6) and mass-spec protein abundance (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible AMOTL2 RNA expression–survival associations across cancer types. High AMOTL2 expression shows unfavorable associations in BLCA and ACC, but favorable associations in UVM, UCS, LGG and SCLC. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify UVM as the clearest survival context for AMOTL2 RNA expression.
This table summarizes AMOTL2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 9. The strongest signals are observed in COAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for AMOTL2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. AMOTL2 shows lower tumor expression in THCA, KICH, UCEC, LUSC and BRCA and higher tumor expression in COAD. The COAD box plot shows higher AMOTL2 RNA expression in tumor versus normal tissue (log2 FC = +1.082, t-test p < 0.001).
This table shows molecular features associated with AMOTL2 in patient tissues and cancer cell lines. In patient samples, AMOTL2 shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set. In cancer cell lines, AMOTL2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and LARGE_INTESTINE.
